Target Name: DHRS3
NCBI ID: G9249
Review Report on DHRS3 Target / Biomarker Content of Review Report on DHRS3 Target / Biomarker
DHRS3
Other Name(s): SDR16C1 | Retinal short-chain dehydrogenase/reductase 1 | short chain dehydrogenase/reductase family 16C member 1 | DHRS3 variant 1 | retinol dehydrogenase 17 | SDR1 | short-chain dehydrogenase/reductase 1 | OTTHUMP00000001866 | dehydrogenase/reductase member 3 | dehydrogenase/reductase 3 | Retinol dehydrogenase 17 | Rsdr1 | Short-chain dehydrogenase/reductase 1 | Short-chain dehydrogenase/reductase 3 | DD83.1 | retSDR1 | retinal short-chain dehydrogenase/reductase 1 | Short chain dehydrogenase/reductase family 16C member 1 | Short chain dehydrogenase/reductase family 16C, member 1 | Dehydrogenase/reductase 3, transcript variant 1 | dehydrogenase/reductase (SDR family) member 3 | Short-chain dehydrogenase/reductase 3 (isoform 1) | RDH17 | DHRS3_HUMAN

Understanding DHRS3: Potential Drug Target Or Biomarker

DHRS3 (Dihydroorotatory Syndrome Subtype 3) is a rare genetic disorder that is characterized by a deficiency of dopamine (D2) receptors, which are responsible for transmitting signals from the brain to the rest of the body. The DHRS3 gene has not yet been fully studied , but it is known to be located on chromosome 16 and to encode a protein known as DHRS3.

The DHRS3 protein is a key component of the dopamine system, as it helps to regulate the levels of dopamine in the brain. It is made up of 1,942 amino acids and has a calculated molecular weight of 21.9 kDa. The protein is expressed in the brain and is involved in the development and maintenance of normal dopamine function.

One of the most interesting aspects of DHRS3 is its potential as a drug target or biomarker. The deficiency of dopamine receptors that is associated with DHRS3 has been shown to contribute to the development of various neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, and depression. Therefore, targeting the DHRS3 protein with drugs that can restore dopamine function could be a promising approach to treating these disorders.

In addition to its potential therapeutic uses, DHRS3 may also be a useful biomarker for the diagnosis of these disorders. The deficiency of dopamine receptors that is associated with DHRS3 is also known to be associated with certain genetic mutations, which could be used to diagnose the disease in individuals who are carrying these mutations. Additionally, the levels of DHRS3 protein in the brain may be affected by certain drugs, which could be used to identify potential drug targets for treating DHRS3.

Overall, DHRS3 is a complex and interesting protein that has the potential to be a drug target or biomarker. Further research is needed to fully understand its role in the development and treatment of DHRS3 and to develop effective treatments for this rare disorder.

Protein Name: Dehydrogenase/reductase 3

Functions: Catalyzes the reduction of all-trans-retinal to all-trans-retinol in the presence of NADPH

The "DHRS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHRS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DHRS4 | DHRS4-AS1 | DHRS4L1 | DHRS4L2 | DHRS7 | DHRS7B | DHRS7C | DHRS9 | DHRSX | DHTKD1 | DHX15 | DHX16 | DHX29 | DHX30 | DHX32 | DHX33 | DHX34 | DHX35 | DHX36 | DHX37 | DHX38 | DHX40 | DHX57 | DHX58 | DHX8 | DHX9 | DIABLO | Diacylglycerol Acyltransferase (DGAT) | Diacylglycerol kinase | DIAPH1 | DIAPH2 | DIAPH3 | DIAPH3-AS1 | DICER1 | DICER1-AS1 | Dickkopf protein | DIDO1 | DiGeorge syndrome critical region gene 9 | Dimethylaniline monooxygenase [N-oxide-forming] | DIMT1 | DINOL | DIO1 | DIO2 | DIO2-AS1 | DIO3 | DIO3OS | DIP2A | DIP2A-IT1 | DIP2B | DIP2C | DIP2C-AS1 | Dipeptidase | Dipeptidyl-Peptidase | DIPK1A | DIPK1B | DIPK1C | DIPK2A | DIPK2B | DIRAS1 | DIRAS2 | DIRAS3 | DIRC1 | DIRC3 | DIRC3-AS1 | DIS3 | DIS3L | DIS3L2 | DISC1 | DISC1FP1 | DISC2 | Disintegrin and Metalloproteinase domain-containing protein (ADAM) (nospecified subtype) | DISP1 | DISP2 | DISP3 | DIXDC1 | DKC1 | DKFZp434L192 | DKFZp451A211 | DKFZp451B082 | DKFZP586I1420 | DKK1 | DKK2 | DKK3 | DKK4 | DKKL1 | DLAT | DLC1 | DLD | DLEC1 | DLEU1 | DLEU2 | DLEU2L | DLEU7 | DLEU7-AS1 | DLG1 | DLG1-AS1 | DLG2 | DLG3 | DLG3-AS1 | DLG4